Viracta Other Non Cash Items from 2010 to 2024

VIRX Stock  USD 0.14  0.01  6.67%   
Viracta Therapeutics Other Non Cash Items yearly trend continues to be fairly stable with very little volatility. Other Non Cash Items is likely to outpace its year average in 2024. During the period from 2010 to 2024, Viracta Therapeutics Other Non Cash Items regression line of annual values had r-squared of  0 and arithmetic mean of  10,030,664. View All Fundamentals
 
Other Non Cash Items  
First Reported
2005-09-30
Previous Quarter
-223 K
Current Value
1.2 M
Quarterly Volatility
524.5 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Viracta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 1.14. Viracta financial statements analysis is a perfect complement when working with Viracta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viracta Therapeutics Correlation against competitors.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Latest Viracta Therapeutics' Other Non Cash Items Growth Pattern

Below is the plot of the Other Non Cash Items of Viracta Therapeutics over the last few years. It is Viracta Therapeutics' Other Non Cash Items historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viracta Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Non Cash Items10 Years Trend
Very volatile
   Other Non Cash Items   
       Timeline  

Viracta Other Non Cash Items Regression Statistics

Arithmetic Mean10,030,664
Geometric Mean3,451,550
Coefficient Of Variation241.24
Mean Deviation15,028,668
Median3,151,000
Standard Deviation24,198,117
Sample Variance585.5T
Range104.5M
R-Value0.04
Mean Square Error629.8T
R-Squared0
Significance0.90
Slope189,962
Total Sum of Squares8197.7T

Viracta Other Non Cash Items History

2024-2 M
2023-2.1 M
2022-626 K
202188.2 M
202012 K
20192.4 M
20183.2 M

About Viracta Therapeutics Financial Statements

Viracta Therapeutics investors use historical fundamental indicators, such as Viracta Therapeutics' Other Non Cash Items, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viracta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Non Cash Items-2.1 M-2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.